VeriTeQ's Chairman and CEO, Scott R. Silverman, and Board Member, Daniel E. Penni, Purchase Collectively More Than 11 Million Shares of the Company's Stock at Market Price

DELRAY BEACH, Fla., April 23, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ" or the "Company") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that its Chairman and Chief Executive Officer, Scott R. Silverman, and Daniel E. Penni, a member of its Board of Directors, have purchased collectively more than 11 million shares of common stock from the Company at the market price.

"I strongly believe in the Company's prospects and business opportunities that lie ahead," stated Silverman. "With the continued growth of our Q Inside Safety Technology, especially in breast implants, as well as some exciting potential new partnerships on the horizon, I continue to increase my equity position through direct investment into the Company."

Q Inside Safety Technology, which acts as an electronic serial number within implanted medical devices, is currently being used within Establishment Labs' ("EL") Motiva Implant Matrix® breast implants. Q Inside Safety Technology enables physicians and patients to access a secure, online database to retrieve implant-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the device manufacturer. EL markets its CE marked breast implants throughout Europe, the United Kingdom, Latin America and Asia.

About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit

Statements in this press release that are not purely historical facts, including statements about our beliefs, intentions or future expectations, may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as "may", "expect", "anticipate", "intend", "estimate" or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward looking statements involve risks and uncertainties and are subject to change at any time, and that our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ's ability to continue to raise capital to fund its operations; VeriTeQ's ability to successfully commercialize its Q Inside Safety Technology; as well as other risks or events beyond VeriTeQ's control. Additional information about these and other factors may be described in VeriTeQ's Form 10-K, filed on April 14, 2015; and future filings with the Securities and Exchange Commission. VeriTeQ undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: VeriTeQ Allison Tomek, 561-846-7003

Source:VeriTeQ Corporation